An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms OpenACT
- Sponsors Dendreon Corporation
- 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Aug 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 08 Aug 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.